<DOC>
	<DOCNO>NCT02830152</DOCNO>
	<brief_summary>Intracerebral hemorrhage ( ICH ) patient non-valvular atrial fibrillation ( NVAF ) pose particular dilemma thromboprophylaxis . Left atrial appendage occlusion ( LAAO ) non-pharmacological approach prevent cardiac embolism NVAF . The risk-benefit ratio LAAO patient NVAF ICH unknown . The aim STROKECLOSE ass effect LAAO reduce incidence stroke , bleed cardiovascular mortality patient NVAF prior ICH .</brief_summary>
	<brief_title>Prevention Stroke Left Atrial Appendage Closure Atrial Fibrillation Patients After Intracerebral Hemorrhage</brief_title>
	<detailed_description>Methods/design : A multicenter prospective randomize open-label clinical trial blind outcome evaluation ( PROBE design ) blind safety outcome assessment . The active comparison LAAO test medical therapy 2:1 stratified randomization . Study population : Patients ICH within 6 month prior enrollment NVAF increase risk stroke systemic embolism , indicate CHA2DS2VASc score &gt; 2 . In total 750 patient include . Active enrollment ensue 3 year follow 5 year follow-up long-term follow-up 10 year . Intervention control : The intervention group treat LAAO , use Amplatzer Amulet device . Implantation require catheterization procedure use venous access transseptal puncture guide angiography , fluoroscopy transesophageal echocardiography ( TEE ) intracardiac echocardiography ( ICE ) . Recommended post-implant antithrombotic therapy include aspirin ( ASA ) therapy least 6 month , without clopidogrel first 45 day implantation . The control group receive medical therapy , deliver accord national standard guideline treat physician ' discretion . This may include oral anticoagulation ( OAC ) ( vitamin-K antagonist , VKA ) , non-VKA OAC , antiplatelet therapy antithrombotic therapy . Main study outcome : The primary outcome composite endpoint stroke ( ischemic hemorrhagic ) , systemic embolism , life-threatening major bleed all-cause mortality , assess least two year . Secondary outcome examines various early late safety outcome parameter .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Cerebral Hemorrhage</mesh_term>
	<criteria>A diagnosis paroxysmal , persistent longstanding NVAF CHA2DS2VASc score &gt; 2 . Clinical CT/MRI evidence ICH within 6 month less 4 week prior enrollment . Age &gt; 18 year . Signed informed consent . ICH secondary vascular malformation tumor Estimated life expectancy le 1 year eligibility assessment mRS &gt; 3 enrollment Contraindications LAAO known time enrollment , LAA thrombus systemic infection , prior surgical LAA excision Planned combined interventional procedure time enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Stroke</keyword>
	<keyword>intracerebral hemorrhage</keyword>
	<keyword>leave atrial appendage occlusion</keyword>
	<keyword>atrial fibrillation</keyword>
	<keyword>oral anticoagulation</keyword>
	<keyword>preventive therapy</keyword>
</DOC>